Edition:
United States

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

2.41USD
4:00pm EDT
Change (% chg)

$-0.02 (-0.82%)
Prev Close
$2.43
Open
$2.47
Day's High
$2.47
Day's Low
$2.35
Volume
155,652
Avg. Vol
130,082
52-wk High
$6.71
52-wk Low
$2.35

Chart for

About

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular... (more)

Overall

Beta: 0.26
Market Cap(Mil.): $230.19
Shares Outstanding(Mil.): 84.01
Dividend: --
Yield (%): --

Financials

  ELGX.OQ Industry Sector
P/E (TTM): -- 37.75 30.58
EPS (TTM): -0.86 -- --
ROI: -23.52 14.28 12.84
ROE: -105.64 17.46 15.02

BRIEF-Endologix Reports Q1 Loss Per Share $0.24

* Q1 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S

May 02 2018

BRIEF-Endologix Appoints John Onopchenko As Chief Executive Officer

* ENDOLOGIX APPOINTS JOHN ONOPCHENKO AS CHIEF EXECUTIVE OFFICER

May 02 2018

BRIEF-Endologix Reports Positive Results From Global Encore Analysis With Polymer Endovascular Aneurysm Repair

* ENDOLOGIX INC - POSITIVE RESULTS FROM GLOBAL ENCORE ANALYSIS WITH POLYMER ENDOVASCULAR ANEURYSM REPAIR USING OVATION ABDOMINAL STENT GRAFT SYSTEMS Source text for Eikon: Further company coverage:

Mar 19 2018

BRIEF-Endologix Inc CEO John McDermott Steps Down

* JOHN MCDERMOTT STEPS DOWN AS CHIEF EXECUTIVE OFFICER OF ENDOLOGIX, INC.

Feb 21 2018

BRIEF-Endologix Posts Q4 Loss Per Share $0.17

* ENDOLOGIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

Feb 21 2018

Competitors

Earnings vs. Estimates